Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Sb. x. s., x. 46/2008 Sb. x. x. x č. 47/2012 Xx. m. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. listopadu 2011 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx v platnost x xxxxxxx x xxxxxxx 34 odst. 3 Úmluvy dne 1. xxxxx 2012 x xxxxx xxxx xxxxxxxxx v xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2011 a xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s.
MEZINÁRODNÍ XXXXXX PROTI DOPINGU XX SPORTU
Příloha X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Paříž, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK A XXXXX DOPINGU XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX KODEX
Platný xx 1. ledna 2012
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, X4.5 a X6(x) x Xxxxxxxxxx xxxxx X1, M2 x X3.
LÁTKY X XXXXXX ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX) |
XXXXXXXX LÁTKY
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (např. léčiva x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx po ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx léky), je xxxxxxxx xxxxx.
X1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x jejich metabolity x xxxxxxx, xxx xx x omezením xxxxx na ně:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-5-en-3β,17α-diol | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
xxxxxxx-5-xx-3α,17β-xxxX | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx anabolické xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" se xxxxxxxx x látce, kterou xxxx není xxxxxxxx xxxxxxx produkovat xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně. |
S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X PŘÍBUZNÉ XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. erytropoetin (EPO), xxxxxxxxxxx (dEPO), xxxxxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), methoxypolyethylenglykol-epoetin xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), stejně jako xxxxxxxxx jiné xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových vláken;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx optických xxxxxxx) jsou xxxxxxxx xxxxx salbutamolu (maximálně 1600 xxxxxxxxxx za 24 xxxxx), formoterolu (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x salmeterolu pokud xxxx xxxxxx x xxxxxxxx v xxxxxxx x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.
Přítomnost xxxxxxxxxxx v xxxx x koncentraci xxxxx xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 30 ng/ml xxxxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx použití, ale xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx způsoben užíváním xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx výše xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, xxxxxxxxx, xxxxxxxx, testolacton, xxx xx x xxxxxxxx xxxxx na xx.
2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx peroxizomovými xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) agonists/ (xxxx. GW 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, které xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Soutěži, xxxxxxxx Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx prahovým limitem (xx. formoterol, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx nebo jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx látku xxxxx x xx, která xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
XXXXXXXX METODY
M1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx nebo xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), perfluorochemikálie x xxxxxxxxxxx (XXX13), xxx xx s xxxxxxxx xxxxx xx xx. Xxxxxxxx kyslíku xxxxxxxx není.
X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx integritu a xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx zakázané. To xxxxxxxx záměnu a/nebo xxxxxx (např. proteázami) xxxx, xxx xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých v xxxxxxx xxxxxxxxxxxx zákroků xxxx klinických xxxxxxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxx, manipulace x xxxxxxxxx xxxxxxxxxxx množství xxxx xxxx do xxxxxxxxx systému xx xxxxxxxx.
X3. XXXXXX XXXXXX
X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx následující:
1. Xxxxxxxx nukleových kyselin xxxx xxxxxx sekvencí;
2. Použití normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx kategorií XX xx X5 a X1 až M3 xxxxxxxxx výše xxxx Xxx Xxxxxxx zakázané x následující xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx (xxxxxx obou jejich xxxxxxxxxx xxxxxxxxx xxxxxxx) xxxx zakázaná, x xxxxxxxx derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, krotetamid, xxxxxxxxx, mefentermin, metamfetamin (x-), methylendioxyamfetamin, methylendioxymetamfetamin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx látkou.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx za Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Katin xx xxxxxxxx pouze xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Efedrin x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx
X7. XXXXXXXXX
Zakázané xx xxxxxxxxxxx:
Buprenorfin, xxxxxxxxxxxxx, diamorfin(heroin), fentanyl x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, xxxxxxxxx, pentazocin, xxxxxxx.
S8. KANABINOIDY
Xxxxxxxx (xxxx. xxxxx, xxxxxx x marihuana) xxxx syntetický xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) x kanabimimetika (xxxx. "Xxxxx" /obsahující XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX V XXXXXXXX XXXXXXXX |
P1. XXXXXXX
Xxxxxxx (xxxxxx) xx zakázaný xxxxx Xxx Soutěži x xxxxxxxxxxxxx sportech. Detekce xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. BETA-BLOKÁTORY
Xxxxx xxxx jinak určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx.
∙ Automobilový sport (XXX)
∙ Xxxxxxxx (xxxxxxx discipliny) (WCBS)
∙ Xxxxx (FMB)
∙ Xxxx (XXX)
∙ Xxxxxxx x xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (FAI)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky a X-xxxxx,x snowboard U-rampa x "xxx xxx"
∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX)
∙ Střelba (ISSF, XXX) (zakázané xxxx Xxxx soutěž)
∙ Xxxxx (WDF)
∙ Xxxxx motorismus (XxX)
Xxxx-xxxxxxxxx zahrnují následující xxxxx:
Acebutolol, alprenolol, xxxxxxxx, betaxolol, bisoprolol, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx č. 97/2012 Xx. m. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx od 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora uvedeného xxxxxxxx předpisu.